Patients With End-Stage Renal Disease, Atrial Fibrillation Have Unique Considerations When Starting Anticoagulation Therapy

Assessing stroke benefit and net clinical benefit of anticoagulation is essential in patients with end-stage renal disease and atrial fibrillation.

In an interview with Pharmacy Times, Zachary Noel, PharmD, BCCP, discussed the presentation at the American Society of Health-System Pharmacists 2021 Midyear Meeting titled "Direct Oral Anticoagulant Dilemmas: Stroke Prevention for Atrial Fibrillation in the Oldest Old and Patients with End-Stage Renal Disease."

In the interview, Noel discussed specific considerations for patients with end-stage renal disease and atrial fibrillation, recommendations for anticoagulation initiation, and how to best assess stroke risk in these populations.

Related Videos
Senior Male Research Scientist is Using a Tablet Computer in a Modern High-Tech Laboratory. Genetics and Pharmaceutical Studies and Researches | Image Credit: Gorodenkoff -
Portrait of a smiling female pharmacist, male colleague working with drugs in the background. | Image Credit: bnenin -
Related Content
© 2023 MJH Life Sciences

All rights reserved.